Welcome to our dedicated page for Intercure Ltd. news (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure Ltd. stock.
InterCure Ltd. (INCR), also known as InterCure (dba Canndoc), is a pharmaceutical cannabis company focused on GMP-certified, pharma-grade medical cannabis. This news page aggregates company announcements, press releases and market updates so readers can follow how InterCure’s vertically integrated seed-to-sale model and international partnerships develop over time.
News items commonly include financial results, where InterCure reports revenue, Adjusted EBITDA and cash metrics for periods such as full fiscal years and half years. These releases often discuss the performance of its cannabis segment, the impact of external events on operations, and the role of compensation from Israeli authorities related to war-damaged facilities.
Another major category is strategic transactions and partnerships. InterCure has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium medical cannabis technology and brand company with partnerships with leading American cannabis operators, and a strategic investment and collaboration with Cannasoul R&D Ltd. focused on evidence-based cannabis therapeutics. Additional news covers the expansion of its partnership with the Cookies brand into Germany and other European markets, as well as agreements to cultivate, manufacture, import and distribute branded products through EU-GMP facilities and licensed pharmacies.
Corporate governance and financing developments also appear in the news feed, such as changes in board leadership, private placement financings, loans from Israeli banks and participation in industry conferences. For investors and observers tracking the pharmaceutical cannabis sector, this page provides a centralized view of InterCure’s operational updates, strategic moves and regulatory disclosures over time.
Summary not available.
InterCure reported strong financial results for the fourth quarter and fiscal year 2021, achieving record revenues of $33 million and $89 million respectively, representing year-over-year growth of almost 200% and over 230%. The Adjusted EBITDA also showed significant progress with $9 million in Q4 and $23 million for the year, reflecting increases of 140% and 250% YoY. The company maintained a solid cash position of $89 million and experienced six consecutive quarters of positive cash flow, with expectations of continued revenue growth into 2022.
InterCure (NASDAQ: INCR) will release its fourth quarter fiscal 2021 financial results on April 4, 2022, before market open. The company, recognized as Israel's largest licensed cannabis producer through its subsidiary Canndoc, is the fastest-growing cannabis firm outside North America. InterCure will host a live conference call and webcast at 8:30 am ET the same day to discuss these results, with details available via their website. This announcement highlights InterCure's ongoing growth and leadership in the cannabis market.
InterCure Ltd (NASDAQ: INCR) announced the release of its fourth quarter 2021 financial results on March 31, 2022, with a subsequent webcast scheduled for April 4, 2022, at 8:30 a.m. ET. The company, a leading cannabis producer in Israel, highlights its growth strategy and recent milestones. InterCure operates through its subsidiary, Canndoc, which is the largest licensed cannabis producer in Israel. The company emphasizes its high-margin, vertically integrated model and market-leading distribution network.
InterCure and Clever Leaves have formed a multi-year agreement to cultivate, market, and distribute pharmaceutical-grade medical cannabis across the EU, Australia, and Israel. InterCure will utilize Clever Leaves’ high-THC cannabis flowers to expand its product offerings in various medical markets, particularly in Israel. This partnership aims to leverage both companies' strengths in distribution and product development, enhancing their international reach and compliance with local regulations. The collaboration highlights a commitment to quality and patient needs in the medical cannabis sector.
InterCure Ltd (NASDAQ: INCR) announced that its CEO, Alexander Rabinovitch, will participate in the ROTH Capital’s 34th Annual Conference on March 15, 2022. He will engage in a One-on-One Fireside Chat at 9:30 AM PT. InterCure, operating under the brand Canndoc, is a leading cannabis company outside North America and Israel’s largest licensed cannabis producer. The company focuses on GMP-certified, pharmaceutical-grade medical cannabis products and utilizes a vertically integrated 'seed-to-sale' model and strong international partnerships.
InterCure has signed a definitive agreement with Altman Health to enter the CBD wellness market in Israel, following a recent government decision to remove CBD from the Dangerous Drugs Act. This partnership aims to manufacture and distribute high-quality CBD products, including those of Charlotte's Web. InterCure, known for its pharmaceutical-grade medical cannabis, is well-positioned with a robust distribution network. Altman Health, a leader in nutritional supplements, has extensive retail presence, ensuring significant market access for CBD products in Israel.
InterCure has announced the acquisition of Cann Pharmaceutical Ltd. ("Better") for USD 35 million, aiming to enhance its position as a leader in the pharmaceutical-grade medical cannabis market. This strategic acquisition is expected to boost InterCure's global reach and product offerings, leveraging Better's unique strains and cultivation expertise. The transaction is structured as a share swap, maintaining a valuation of USD 10 per share, which aligns with previous transactions. Closing is expected in Q3 2022, pending regulatory approvals.
InterCure reported record preliminary revenue of over CAD$31 million (NIS 77 million) for Q4 2021, a 250% year-over-year increase. This marks the eighth consecutive quarter of double-digit growth, with an annualized run rate of $124 million. The company anticipates continued increases in operating profit, EBITDA, and revenue growth into 2022. Additionally, InterCure is expanding its market presence with openings in Europe and has increased its pharmacy locations to 20 in Israel, capturing approximately 30% of the medical cannabis market.
InterCure Ltd (NASDAQ: INCR) announces a strategic partnership with Cookies to launch retail locations in Austria and the U.K. in early 2022. This multi-year agreement will enable InterCure to establish Cookies stores and medical cannabis pharmacies, leveraging its supply chain expertise to cater to the medical cannabis market in Europe. InterCure, already thriving in Israel, plans to replicate its successful business model as the European cannabis landscape evolves favorably.